SeanKhozin_hi-rez
Ten Years In, Project Data Sphere Is Snowballing
Project Data Sphere, an open access data sharing initiative, is expanding into closed access preclinical research and developing AI models that can benefit drug developers.  Continue Reading..
  • Partnering To Address 'Huge' Opportunities In Women's Health
    6/14/2024

    Nonprofit research foundations can offer scientific expertise and support for biopharmaceutical drug development and clinical programs, helping companies improve new and existing drugs for women.

  • Where Are They Now? Otsuka
    5/30/2024

    Otsuka Precision Health, a new subsidiary focused on digital therapeutics and other tech-enabled solutions for patients, is a continuation of the company's broader mission described by an Otsuka executive in the pages of Life Science Leader eight years ago.

  • Drug Discovery And Development, Powered By Physician Intelligence
    5/15/2024

    For Nuvalent CEO James Porter, physician intelligence is more important than artificial intelligence in discovering and developing new therapies that tackle key unmet needs among cancer patients.

  • Where Are They Now? SQZ Biotech
    5/1/2024

    SQZ Biotech, a novel cell therapy company with Big Pharma backing, is no more. However, the company's science, and its founding CEO, will continue on under new auspices.

  • Reviva Pharma's Novel Funding Approach In Schizophrenia
    4/25/2024

    Reviva Pharma CEO Laxminarayan Bhat, Ph.D. found a novel way to build an investor base for his company during a time when Big Pharma was exiting complicated CNS diseases. Now, Reviva has a late-stage schizophrenia candidate just as CNS is back in vogue.

  • Companies To Watch: OSE Immunotherapeutics
    4/22/2024

    OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need.

  • A View From The Co-Chair Of Israel's Biopharma Industry Trade Organization
    3/28/2024

    Yaacov Michlin, co-chair of the IATI, discusses the advantages and disadvantages of Israel’s biopharma industry, the industry impact of the war in Gaza, and the difference between the U.S. and Israel regarding Chinese CDMOs.

  • Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals
    3/22/2024

    AstraZeneca's $2.4 billion acquisition of Fusion Pharma is the third billion dollar radiopharmaceuticals deal in recent months. John Valliant, Fusion's founder and CEO, explains why alpha-emitters are better than beta-emitters, and why radiopharmaceuticals are poised for substantial growth.

  • Where Are They Now? Novo Nordisk
    3/18/2024

    In a few short years, Novo Nordisk has gone from belt-tightening to parachute pants, and is now replaying a GLP-1 competition with Eli Lilly that kicked off with Victoza and Trulicity ten years ago.

Ben Comer_2022_1

Ben Comer

Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.